LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.
MedCity INVEST 2022at The Ritz Carlton Chicago is a 3 day gathering with numerous opportunities for in-person networking and learning around the latest technologies and investment trends from VCs and successful entrepreneurs.
By Frank Vinluan Wednesday, March 23, 2022 7:57 PM
The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.
By Michael Schroeder Wednesday, March 23, 2022 7:27 PM
The new organization combining InterWell, Fresenius Health Partners and Cricket Health is valued at $2.4 billion with a total addressable market of $170 billion, more than $6 billion of medical costs under management, and over 100,000 covered lives, according to the combined company.
To protect mothers, we must invest in a culturally relevant, community-based continuum of care. We must unite policymakers, advocates, physicians, health systems, payers, midwives, doulas, and community organizations in order to develop a standardized continuum of care.
By Brian Rinker, Kaiser Health News Wednesday, March 23, 2022 2:42 PM
Startup experts and clinicians working on the front lines of the drug and overdose epidemic doubt the flashy Silicon Valley technology will ever reach people in the throes of addiction who are unstably housed, financially challenged, and on the wrong side of the digital divide.
BioCoach will use its $4 million seed funding from SecretLab LLC founder Jason Bright to scale its platform that tackles prediabetes by offering customized diet coaching, including meal plans and grocery lists.
By Frank Vinluan Wednesday, March 23, 2022 1:42 PM
LifeMine Therapeutics, a company that analyzes fungal genomes to find molecules that have potential as new medicines, has raised $175 million in financing. Among the investors is GlaxoSmithKline, which is teaming up with the biotech startup in a multi-target drug discovery alliance.
Early indications show that remote patient monitoring holds promise in advancing value-based care. But healthcare providers and practice managers need to consider several factors before they begin to integrate RPM and wearables into their practices and decision-making processes.
In this episode of the MedCity Pivot Podcast, Jonathan Bush talks about his latest venture - Zus Health - through which he wants to help digital health companies share data to create a universal patient off of which new products can be created to serve payers, providers and others with the ultimate goal of improving patient outcomes.
No comments